Composition for cancer diagnosis

Inventors: Hyung Keun Lee (Seoul, KR); Dong Ki Lee (Seongnam-si, KR); Sung Ill Jang (Seoul, KR); So Young Kim (Suwon-si, KR); A Reum Yeo (Seoul, KR); Jong Kyoung Kim (Pohang-si, KR); Eun-Ju Chang (Seoul, KR)

Assignee: ACURASYSBIO CO., LTD.

G01N33/57525 A61P35/00 G01N33/492 G01N33/566 G01N33/6869 A61K39/001119

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12710425
App. No.: 17/595,665
Filed: Nov 22, 2021
Granted: Aug 18, 2026
Kind: B2
Examiner: AEDER, SEAN E
Art Unit: 1642
USPC: 435/7.23

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure relates to a composition capable of diagnosing cancer, specifically pancreatic cancer or the like, a diagnostic kit comprising the same, and a method of providing information for diagnosis using the composition. Also, the present disclosure relates to a pharmaceutical composition capable of preventing or treating pancreatic cancer.

Claims (4)

1 . A method for diagnosing and treating pancreatic cancer, comprising:

(a) measuring an expression level of interleukin-7 receptor alpha (IL-7RA), or a gene encoding IL-7RA, in peripheral blood mononuclear cells (PBMCs) obtained from a subject suspected of having pancreatic cancer by quantitative PCR to obtain a ΔCt value;

(b) diagnosing pancreatic cancer based on the ΔCt value being lower than a predetermined cutoff value, wherein the predetermined cutoff value is a ΔCt value obtained from PBMC samples of normal controls; and